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Abstract
Solid and hematologic cancers colonized bone produce a number of pathologies. One of the most 
common complications associated with bone-colonized cancer is bone pain. Cancer-associated 
bone pain (CABP) is a major cause of increased morbidity and mortality and diminishes the 
quality of life and affects survival in cancer patients. Current treatments do not satisfactorily 
control CABP and can elicit serious side effects. Thus, new therapeutic interventions are needed to 
manage CABP. However, the mechanisms responsible for CABP are poorly understood. The 
observation that specific osteoclast inhibitors can reduce CABP in patients indicates a critical role 
of osteoclasts in the pathophysiology of CABP. Osteoclasts create an acidic extracellular 
microenvironment by secretion of protons via plasma membrane vacuolar proton pumps during 
bone resorption. In addition, bone-colonized cancer cells also release protons and lactate via 
plasma membrane pH regulators to avoid intracellular acidification resulting from increased 
aerobic glycolysis known as Warburg effect, thus exacerbating the acidic microenvironment. Since 
acidosis is algogenic for primary afferent sensory neurons and bone is densely innervated by 
sensory neurons that express acid-sensing nociceptors, the acidic bone microenvironments can 
evoke CABP. Understanding of the cellular and molecular mechanism by which the acidic 
extracellular microenvironment is created in cancer-colonized bone and the expression and 
function of these acid-sensing nociceptors are regulated may facilitate the development of novel 
therapeutic approaches for management of CABP. In this review, the contribution of the acidic 
extracellular microenvironment created by bone-colonized cancer cells and bone-resorbing 
osteoclasts to excitation and sensitization of sensory nerves innervating bone and elicitation of 
CABP and potential therapeutic implications of blocking the development and recognition of 
acidic extracellular microenvironment will be described.
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1. Introduction
Common solid cancers such as breast cancer, prostate cancer and lung cancer preferentially 
spread to bone [1]. Rare primary bone malignancies such as osteosarcoma, Ewing's sarcoma, 
chondrosarcoma also aggressively expand in bone [2]. Multiple myeloma, which is a 
malignant plasma cell disorder accounting for approximately 10% of all hematologic 
cancers, exclusively colonizes bone [3]. These bone-colonizing cancers induce the 
development of either osteolytic, osteosclerotic or mixed bone disease by disrupting the 
homeostasis of bone environment. In addition, they are associated with skeletal-related 
events including bone pain, pathologic fractures, hypercalcemia, spinal cord compressions, 
palliative radiotherapy to bone and surgery to bone to treat or prevent a fracture during the 
clinical course of the disease [4]. Of these, bone pain is one of the most common and 
detrimental complications associated with cancer colonization in bone [5]. Cancer-
associated bone pain (CABP) profoundly diminishes quality of life, impairs host immune 
surveillance and delays recovery from the illness, leading to increased secondary death. 
Accordingly, control of bone pain is a major goal for medical oncologists to achieve in the 
management of cancer patients. However, current treatments for CABP are not satisfactory 
and adequate and have serious side effects. Thus, new effective therapeutic interventions for 
CABP with reduced adverse effects need to be developed. Despite these circumstances, little 
is known about the mechanism of CABP.
Although the mechanism of CABP is poorly understood, accumulating clinical studies have 
shown that the specific inhibitors of osteoclasts, bisphosphonate and denosumab, 
significantly reduce CABP [6, 7]. Osteoclasts are the principal bone resorbing cells in 
physiological and pathological conditions associated with increased bone resorption [8]. 
They play a central role in the pathophysiology of cancer colonization in bone [1]. These 
results collectively suggest that factors released at the tumor-bone interface during 
osteoclastic bone resorption may be an important mechanism of CABP. However, it should 
be noted that suppression of osteoclastic bone resorption fails to prevent the progression of 
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CABP as the disease advances [7], confirming that not only osteoclasts but also cancer cells 
contribute to the pathophysiology of CABP.
In cancer-colonized bone microenvironment, osteoclasts, cancer cells, and cancer-associated 
stromal cells and inflammatory immune cells produce varieties of algogenic mediators that 
can excite and sensitize peripheral nociceptive sensory neurons and evoke pain through 
binding to their cognitive receptors present on the sensory neurons [9–11]. Protons are one 
of these algogenic mediators [9–11]. Of note, osteoclasts release protons via the plasma 
membrane (a3 isoform) vacuolar-H+-ATPase coupled with chloride channels to secrete 
hydrochloric acid to degrade bone minerals during bone resorption [8, 12]. In addition, it has 
been well-recognized that aggressive cancer cells secrete substantial levels of protons/lactate 
into the extracellular environments to avoid intracellular acidification due to elevated aerobic 
glycolysis known as Warburg effect [13]. Thus, protons released from osteoclasts and cancer 
cells co-operatively create an acidic extracellular microenvironment in cancer-colonized 
bone.
Here we will overview the role of the acidic microenvironment created by protons/lactate 
released from bone-resorbing osteoclasts and bone-colonizing cancer cells in the 
pathophysiology of CABP with our recent experimental observations.
2. Acidic extracellular microenvironment in cancer-colonized bone
2.1. Osteoclastogenesis
Osteoclasts are multinucleated giant cells formed by the fusion of mononuclear progenitors 
of the monocyte/macrophage lineage [8]. They are the principal bone resorbing cells and 
play a central role in the formation of the skeleton and regulation of its mass. For osteoclast 
formation from the osteoclast precursors, macrophage colony-stimulating factor (M-CSF) 
and receptor for activation of nuclear factor kappa B (NF-κB) (RANK) ligand (RANKL) 
[14] produced in neighboring osteoblasts or stromal cells are essential [8] (Figure 1). 
RANKL is a member of tumor necrosis factor family and primarily a membrane-bound 
cytokine. Therefore, osteoclast precursors that express receptors for RANKL, RANK, need 
to contact with osteoblasts or stromal cells to differentiate into mature osteoclasts. 
Osteoprotegerin (OPG) is a natural soluble decoy receptor that competes with RANK for 
RANKL and thus inhibits RANKL-induced osteoclast formation and bone resorption [8]. 
The balance between the expression of RANKL and OPG (RANKL/OPG ratio) controls 
osteoclastogenesis and the degree of resulting bone resorption. Mice lacking M-CSF, 
RANKL or RANK showed osteopetrosis due to decreased osteoclastogenesis and 
dysfunction of mature osteoclasts [14]. On the other hand, mice deficient of OPG exhibited 
severe osteopenia due to increased osteoclastogenesis and bone resorption [14]. The 
mutations in the signal peptide region of the RANK protein cause familial expansile 
osteolysis, a rare autosomal dominant disorder characterized by focal areas of enhanced 
bone resorption, and familial Paget s disease [15]. OPG deficiency due to homozygous loss-
of-function mutations within the TNFRSF11B gene is a cause of Juvenile Paget's disease 
[16]. Thus, osteoclasts are evidently the principal causative player in diverse bone disorders.
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2.2. Role of osteoclasts in cancer colonization in bone
In cancer-colonized bone and bone metastasis, osteoclasts are increased and activated to 
destroy bone by factors produced by cancers [1, 17, 18]. Bone destruction, in turn, further 
stimulates the colonization of cancer cells in bone via the release of bone-stored growth 
factors including transforming growth factor-β (TGF-β) and insulin-like growth factors 
(IGFs). This interactive process between bone-colonizing cancer cells and bone-resorbing 
osteoclasts is called “the vicious cycle” (Figure 2). Thus, osteoclasts are a central regulatory 
player in the pathophysiology of cancer colonization in bone and bone metastasis. However, 
their role in CABP remains poorly understood.
2.3. Bone resorption and proton release by mature osteoclasts
Significant reduction of bone pain by the specific inhibitors of osteoclastic bone resorption, 
bisphosphonates and denosumab, in patients with multiple myeloma and solid cancers [6, 7, 
19, 20] indicates a critical role of osteoclasts in the pathophysiology of CABP. Consistent 
with these clinical observations, Honore et al [21] reported that OPG, which inhibits 
osteoclast formation and bone resorption through interfering RANKL binding to RANK [8], 
suppressed CABP using an experimental animal model. We also showed that the most potent 
bisphosphonate zoledronic acid significantly reduced CABP [22]. It is therefore important to 
understand how osteoclasts resorb bone to gain better insights into the mechanism 
underlying CABP.
Bone resorption by mature osteoclasts is a dynamic multi-step process [8]. First, osteoclasts 
migrate and attach tightly to the bone surface targeted for degradation and removal via the 
αvβ3 integrin, thereby forming a tight “sealing zone”. Plasma membrane then polarizes to 
form the resorption organelle, called “ruffled border”. The ruffled border is a unique folded 
highly permeable membrane facing to the resorbing bone surface. To dissolve bone 
minerals, protons (H+) and chloride ions (Cl−) is released via the plasma membrane (a3 
isoform) vacuolar H+-ATPase proton pump [23] and chloride ion-proton anti-porter ClC-7 
[24] clustered in the ruffled border into the resorption lacunae, acidifying the resorptive 
lacunae to a pH of 4.5 [8]. Concomitantly, the cysteine peptidase cathepsin K [25] degrades 
bone matrix. The degraded bone matrix is trans-endocytosed from the resorption lacunae to 
the “functional secretory domain” and released into the extracellular environment [26]. 
Finally, osteoclasts gone through bone resorption detach from the bone surface and undergo 
apoptosis [8].
Our RT-PCR and immuno-fluorescent analysis confirmed that bone-resorbing osteoclasts 
strongly express a3 vacuolar-H+-ATPase on their plasma membrane, while another acid-
secreting tissue, the gastric epithelium exhibited marginal expression of a3 vacuolar-H+-
ATPase (unpublished data). On the other hand, the gastric epithelium displayed high 
expression of p-type-H+-ATPase [27], while the expression of p-type-H+-ATPase in 
osteoclasts was undetectable. These data suggest that algogenic protons released from bone-
resorbing osteoclasts via a3 vacuolar-H+-ATPase into the extracellular microenvironment 
likely impact pH-sensitive peripheral nerve fibers and directly contribute to bone pain. In 
support of this notion, we reported that the non-selective vacuolar-H+-ATPase inhibitor, 
bafilomycin A1 reduces inflammatory bone pain [28]. Moreover, we recently found that 
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bafilomycin A1 blocked the development of acidic environment in cancer-colonized bone 
determined by acridine orange staining [29] and significantly reduced CABP (unpublished 
data). Of interest, the p-type-H+-ATPase inhibitor, rabeprazole [30] that is widely used for 
the treatment of gastric pain failed to suppress CABP. The pathophysiology of CABP may 
be thus unique compared with that of other types of pain because of the contribution of 
osteoclast a3 vacuolar-H+-ATPase. Many classes of inhibitors of osteoclast proton pump for 
the treatment of osteoporosis are currently developed and tested in pre-clinical and clinical 
settings. It is expected that these agents not only inhibit bone resorption but also alleviate 
CABP.
2.4. Proton and lactate release by cancer cells
The failure of inhibitors of osteoclastic bone resorption to block the progression of CABP in 
patients [7, 20] and tumor-bearing animals [21, 22] indicates that osteoclasts are not the only 
cells contributing to CABP. Undoubtedly, cancer cells, inflammatory cells and immune cells 
contribute to the pathophysiology of CABP as well. Cancer cells produce varieties of 
nociceptive substances including protons, proteases, glutamate, lysophosphatidic acid, 
prostaglandins, nerve growth factors, endothelin, bradykinin, extracellular adenosine 
triphosphate and pro-inflammatory cytokines and chemokines such as interleukins, tumor 
necrosis factors and macrophage inflammatory protein-1 [9–11]. Among these, the 
contribution of protons released from cancer cells, in addition to osteoclasts, to the 
pathophysiology of CABP will be discussed here.
Some regions of cancer environment are hypoxic due to inadequate oxygen delivery, which 
limits oxidative phosphorylation that efficiently produces ATP via glucose metabolism in the 
mitochondria in normal cells [13]. To meet increased requirements for ATP and metabolic 
intermediates and precursors to maintain their aggressiveness, hypoxic cancer cells shift 
their energy metabolism to glycolysis that is much less energy-efficient but independent of 
oxygen. The elevated aerobic glycolysis, known as Warburg effect, consumes high glucose 
and produce substantial amounts of lactate that lowers intracellular pH [13]. To avoid 
intracellular acidification, cancers actively extrude lactate and protons via plasma membrane 
pH regulators such as monocarboxylate transporter 1 and 4 (MCT1 and MCT4), Na+/H+ 
exchangers, anion exchangers, carbonic anhydrases, V-H+-ATPase, Na+/HCO3− co-
transporters and HCO3−transporter, creating acidic extracellular cancer microenvironment 
[31]. We showed high-metastatic B16 mouse melanoma cells expressed increased levels of 
the a3 isoform V-H+-ATPase compared to the low-metastatic B16 parental cells. Knockdown 
of a3 V-H+-ATPase suppressed invasiveness and migration and significantly decreased lung 
and bone metastases [32], suggesting that a3 V-H+-ATPase promotes distant metastasis of 
B16 melanoma cells by creating acidic environments via proton secretion. From these 
results, we propose that inhibition of the development of cancer-associated acidic 
environments by suppressing a3 V-H+-ATPase could be a novel therapeutic approach for the 
treatment of cancer metastasis. The potential of the inhibitors of aerobic glycolysis (Warburg 
effect) [33] and these proton pumps [31] as anti-cancer drugs has been extensively explored. 
However, the effects of these inhibitors on CABP are unknown. Determination of the effects 
of these inhibitors on CABP may facilitate to the development of drugs with both anti-
cancer and analgesic actions.
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MCT1 and MCT4 are two of the major proton-coupled lactate symporters mediating 
bidirectional lactate transport across the plasma membrane [34]. Many cancer cells express 
MCT1 and MCT4 through which substantial amounts of lactate resulting from Warburg 
effect are released [35]. Of note, MCT expression in cancer is correlated with outcome of 
breast cancer patients [36]. Thus extracellular lactate levels are likely elevated in cancer 
environment. Recent studies reported that lactate released via MCTs from astrocytes is not a 
waste of glycolysis but rather an energy source shuttling between astrocytes and neurons 
[37, 38], suggesting that lactate is a critical regulator of neuronal function. Therefore, 
nociceptive sensory neurons can be also activated by lactate released via MCTs from 
aggressive cancer cells to evoke CABP. We have recently found that MCT1 and MCT4 are 
expressed in multiple myeloma cells isolated from patients and several lines of breast cancer 
cells and multiple myeloma cells (unpublished data). These cancer cells secreted lactate via 
MCTs and lower extracellular pH. Furthermore, dorsal root ganglion (DRG) sensory 
neurons also expressed MCT1 and MCT4. Acidic environment (pH 6.5) created by lactate 
stimulated an excitation of DRG sensory neuronal cells determined by intracellular Ca2+ 
mobilization using Fura-2 calcium imaging assay. More importantly, we found that the non-
specific MCT antagonist, α-cyano-4-hydroxycinnamate (CHC) [39] reduced CABP in an 
animal model. MCT inhibitors such as CHC are also shown to have anti-cancer effects and 
some of them are in Phase I clinical trials for advanced solid tumors and for diffuse large B-
cell lymphoma [35]. Our results together with these earlier results suggest that MCT 
inhibitors could be developed as drugs that inhibit tumor growth and CABP.
3. Acid-sensing machinery in bone
3.1. Innervation of nociceptive sensory neurons in bone
It has been proposed that the densely innervated periosteum is the primary site from which 
bone pain arises. However, patients often complain of bone pain even if cancer localizes to 
bone marrow or mineralized bone and in the absence of evident periosteal involvement [40], 
indicating the presence of sensory nerve fibers in non-periosteal sites in bone. An early 
study using a transmission electron microscopy described by Cooper demonstrated that 
nerve fibers are present in cortical bone [41]. Furthermore, data are accumulating that bone 
is densely innervated [40, 42–44]. Of note, Mach et al reported that the bone marrow had the 
greatest total number of sensory fibers, followed by mineralized bone and then periosteum 
[40]. Consistent with these earlier studies, we also showed that calcitonin gene-related 
peptide (CGRP)-positive sensory neurons innervate the mineralized bone and bone marrow. 
CGRP has been widely used as a marker for sensory neurons and implicated in migraine 
[45]. Mice lacking CGRP showed attenuated responses to nociceptive chemicals and 
inflammation [46].
The sensory neurons innervating bone are distal nerve fibers from a number of 
subpopulations of primary afferent sensory neurons associated with lumbar DRG (L3–L5) 
[40, 47]. These cell populations are largely subdivided by the presence of neurofilament 
(NF) 200-positive (A-δ) and CGRP-positive (A-δ or peptidergic C fibers). Bone can be 
further distinguished by the general lack of innervation by the non-peptidergic 
subpopulation of neurons that bind isolectin B4 (IB4) [47]. Though functional distinction of 
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these neurons is not fully understood, CGRP-positive peptidergic C-fibers detect noxious 
stimuli and are classified as nociceptors [48]. Recent studies demonstrated that CGRP-
positive sensory neurons exhibited the pathological sprouting in the presence of bone cancer 
[49]. Nerve growth factor (NGF) derived from cancer cells and stromal cells is likely 
responsible for the sprouting of sensory neurons, since anti-NGF neutralizing antibody 
blocked the sprouting and reduced CABP [49]. This pathological remodeling of the 
peripheral sensory fibers may exacerbate CABP, making control of CABP difficult. We 
observed similar sprouting of CGRP-positive sensory neurons in bone colonized by breast 
cancer cells and multiple myeloma cells (unpublished data). These results suggest that the 
products in cancer-colonized bone environment promote the sensory neurons innervating 
bone to remodel and progress CABP.
3.2. Acid-sensing receptor
Based on previous and our results, it is likely that the pathological acidic microenvironments 
created by protons/lactate secreted from bone-resorbing osteoclasts and bone-colonizing 
cancer cells up-regulate and activate acid-sensing nociceptors expressed on sensory neurons 
to evoke CABP. Two of the specific and representative pH-sensitive acid-sensing nociceptors 
that are related to acid-induced bone pain are the transient receptor potential channel-
vanilloid subfamily member 1 (TRPV1) and the acid-sensing ion channel 3 (ASIC3) [48].
3.2.1. Transient receptor potential channel-vanilloid subfamily member 1—The 
TRPV1/vanilloid receptor 1 (VR1)/capsaicin receptor, which was cloned from vertebrates by 
Caterina et al [50], is a family member of transient receptor potential (TRP) ion channels 
expressed on a subset of nociceptive sensory neurons. It is activated by heat (>42C) and acid 
(<pH 6.0) and is the only channel that is excited by the vanilloid capsaicin [50, 51]. In bone 
TRPV1 is found to express in osteoblasts and osteoclasts and regulate their differentiation 
and function [52].
Using a mouse model of inflammatory pain [53], we showed that TRPV1 was co-expressed 
on CGRP-positive sensory neurons in DRG. Mice with inflammation in their hind-paw 
exhibited a nociceptive behavior (thermal hyperalgesia) with elevated CGRP mRNA 
expression in the DRG. Treatment by acid (pH 5.5) excited primary DRG sensory neuron 
cells and increased CGRP mRNA expression and protein production in these cells. The 
specific antagonist of TRPV1, 5 -iodoresiniferatoxin (I-RTX), blocked the excitation and the 
acid-increased CGRP expression and production. Further, primary DRG cells isolated from 
TRPV1 −/− mice failed to show an increase in CGRP expression upon treatment with acid. 
Of importance, inflammatory pain was markedly diminished in TRPV1 −/− mice. These 
results collectively suggest that activation of TRPV1 in inflammatory acidic environment 
leads to an up-regulation of CGRP expression, which in turn further increases inflammation 
and pain. Thus, blockade of TRPV1, CGRP or both could be an effective pharmacological 
intervention for acid-associated inflammatory pain.
TRPV1 has been implicated in the pathophysiology of CABP [9, 11, 54]. In preclinical 
models of cancer pain, TRPV1 expression was increased in the ipsi-lateral DRG in the 
presence of cancer in bone [55, 56]. In support of the important role of TRPV1 in CABP, 
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TRPV1 gene disruption or TRPV1 antagonist reduces CABP [57]. Similarly, the specific 
TRPV1 antagonist I-RTX also suppressed CABP [56]. Of interest, the TRPV1 antagonist 
SB366791 was shown to potentiate analgesic effects of morphine on bone cancer pain [58]. 
These data suggest that suppression of TRPV1 activation under the acidic cancer 
environment is a promising therapeutic approach to attenuate CABP. However, preclinical 
and clinical studies revealed that TRPV1 antagonists induce hyperthermia as an adverse 
effect [59]. Attempts to develop or identify antagonists devoid of temperature effects have 
not been successful. In this context, it is noted that recent studies have shown that the 
expression and activity of TRPV1 on the DRG sensory neurons are up-regulated by 
transforming growth factor-β1 (TGF-β1) [60] and insulin-like growth factor-1 (IGF-1) [61]. 
Since TGF-β and IGF-1 are abundantly stored in bone and released as a consequence of 
bone resorption by cancer-activated osteoclasts, expression and activation of TRPV1 on the 
sensory neurons innervating bone may be modulated by these bone-derived growth factors. 
In fact, these studies showed that inhibition of TGF-β [60] or IGF receptor signaling [61] 
reduced CABP due to suppression of TRPV1 activation. Suppression of TRPV1 activity and 
expression by blocking the activity of growth factors released from bone may be an 
alternative approach to attenuate CABP.
3.2.2. Acid-sensing ion channel 3—ASIC3 is a pH sensor predominantly expressed in 
primary afferent sensory neurons [62, 63]. In DRG, ASIC3 expression was increased in 
inflammatory acidic conditions and co-expressed with CGRP in the sensory neurons 
innervating the knee joint, indicating ASIC3 contribution to acute arthritis pain [64]. ASIC3 
was also detected on the CGRP-positive sensory neurons innervating periosteal surface of 
bone [65]. In bone ASIC3 is present in monocytes, osteoclasts and osteoblasts [66]. 
However, its functional role in bone homeostasis is unclear.
A recent study that showed that an injection of the synthetic ASIC3 agonist, 2-guanidine-4-
methylquinazoline into mouse paw induced noxious behaviors in wild-type mice but not 
ASIC3−/− mice [67] provided the evidence that ASIC3 activation is sufficient to evoke pain 
[68]. However, the role of ASIC3 in CABP still remains elusive. We reported that ASCI3 
mRNA expression was up-regulated in DRG associated with CABP in a model of rat 
mammary tumor [55]. In support of our results, Qiu et al [69] recently showed ASIC3 
expression was elevated in DRG using a different model of rat mammary tumor. Although 
these results suggest that ASIC3 is involved in the pathophysiology of CABP, it needs to be 
shown that suppression of increased ASIC3 expression in DRG leads to reduced CABP and 
that CABP is alleviated in ASIC3 knockout mice. We have recently found that, upon acid 
treatment (pH 6.5), primary sensory neuron cells isolated from DRG displayed Ca2+ influx 
(unpublished data), which is a widely-used early indicator for sensory neuron excitation 
[70]. Of note, the specific ASIC3 antagonist APETx2 [71] inhibited Ca2+ influx, indicating a 
critical role of ASIC3 in sensory neuron excitation. Of interest, APETx2 was shown to 
reduce acid-induced and inflammatory pain due to complete Freund's adjuvant in rat [72] 
and slower the progression of the disease in a rat model of osteoarthritis [73]. It is intriguing 
to examine the effects of APETx2 on CABP.
ASIC3 senses mild extracellular acidification (pH 6.8–7.0) [63], while TRPV1 is activated at 
the pH lower than 6.0 [50, 51]. We reported TRPV1 was activated at pH 5.5 [53]. The pH of 
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the acidic environment created by cancer cells is shown to be 6.5–7.0 [31] and that by bone-
resorbing osteoclasts is assumed to be 4.0–4.5 [23]. Sensory neurons innervating bone may 
be excited and sensitized by discriminating mild and strong acidic extracellular 
microenvironment through ASIC3 and TRPV1 in the pathophysiology of CABP, 
respectively (Figure 3).
3.3 Other acid-sensing machineries potentially contributing to CABP
Transient receptor potential (TRP) ion channels are the large families of cellular sensors 
mediating taste perception, thermo-sensation, mechano-sensing and osmolality sensing by 
transducing various physical stimuli into neuronal signals in predominantly C and Aδ 
nociceptors in primary sensory neurons [74]. Further, TRP ion channels also mediate 
transduction of peripheral nociceptive stimuli into pain. Of interest, recent studies described 
that the members of TRP channels are involved in the regulation of skeletal homeostasis 
through affecting intestinal calcium absorption (TRPV6), renal calcium reabsorption 
(TRPV5), and differentiation of osteoclasts (TRPV1, TRPV2, TRPV4, TRPV5), 
chondrocytes (TRPV4) and osteoblasts (TRPV1) [52]. It is thus tempting to propose that 
these family members of TRP channels play a role in acid-induced CABP. However, current 
available evidence suggests that acid unlikely activates these TRPVs except for TRPV1.
TRP Ankyrin 1 (TRPA1) is a non-selective Ca2+ permeable cation channel that uniquely 
possesses 17 ankyrin repeat domains [74]. TRPA1 is predominantly expressed C and Aδ 
nerve fibers. Although still controversial, TRPA1 is proposed to be activated by noxious cold 
temperatures (< 18° C) and mechanical force and some studies reported that TRPA1 
deficient mice showed impaired behavioral responses to cold plate and mechanical stimuli. 
Expression of TRPA1 in bone cells has been unknown but a recent study demonstrated the 
expression of TRPA1 in human odontoblasts [75]. It is unclear whether TRPA1 is activated 
by acid and plays a role in CABP. Notably, however, most neurons that express TRPA1 also 
express TRPV1, raising the possibility that TRPA1 may modulate or partially share the acid-
sensing functions of TRPV1. In case this is proved to be the case, hyperthermia, which is a 
major obstacle in the development of TRPV1 antagonists, may not be a serious problem 
with TRPA1 antagonists.
TRP Melastatin 8 (TRPM8) is expressed in a subset of C and Aδ nerve fibers in DRG, 
trigeminal ganglion and nodose ganglion [74]. In bone, TRPM8 expression was shown in 
osteoblasts, however, its functional role is unknown [76]. TRPM8 is activated by cold 
temperatures (< 15 °C) and cooling compounds such as menthol and icilin and peppermint 
oil. In contrast, it is unclear whether TRPM8 is activated by acid. TRPM8 was initially 
cloned as a molecule that has high homology to a TRP-like channel that was identified in 
prostate cancers [74]. Later, it was found that increased expression of TRPM8 is correlated 
with the aggressiveness of a variety of cancers including prostate, lung, breast, gastric, 
ovarian and liver cancer and melanoma [77]. Since prostate, breast and lung cancers 
preferentially spread to bone and are frequently associated with CABP, it is plausible to 
speculate that TRPM8 contributes to the pathophysiology of CABP. The role of TRPM in 
CABP needs to be elucidated.
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4. Conclusion
Bone is a unique organ in which multinucleated giant osteoclasts continuously secrete 
protons to maintain bone homeostasis in physiological conditions [8]. The secretion of 
protons by osteoclasts is increased in response to the bone-modifying factors produced by 
bone-colonizing cancer cells [1, 17, 18]. Protons and lactate are also secreted by bone-
colonizing cancer cells as a consequence of elevated oxygen-independent glycolysis 
(Warburg effect) [13, 31]. In addition to autonomous secretion of protons, osteoclasts and 
cancer cells may further increase proton and lactate secretion in bone microenvironment that 
is relatively hypoxic [78]. Hypoxia is shown to up-regulate the expression and function of 
the plasma membrane proton/lactate transporters [31]. Therefore, it is likely that cancer-
colonized bone microenvironment readily falls into pathological acidosis and that the 
contribution of acid is more specific and critical in the pathophysiology of CABP than that 
of other types of pain. In addition, accumulating evidence indicates that the acidic 
extracellular microenvironments critically influence malignant behaviors of cancer including 
invasiveness, metastasis, and chemo- and radio-resistance and thus are associated with poor 
prognosis [79, 80]. Accordingly, suppression of the creation of acidic extracellular cancer-
colonized bone microenvironment through inhibition of the function of the proton/lactate 
transporters in osteoclasts and cancer cells seems likely to simultaneously inhibit cancer 
aggressiveness and CABP. Furthermore, pharmacological agents that interfere with the 
activation of acid-sensing nociceptors in sensory neurons associated with bone will be an 
effective and selective therapeutic means for CABP. Finally, development of new analgesic 
drugs for CABP is expected to reduce dosing of opioids that are currently the primary agent 
in the management of cancer pain but cause unwanted adverse effects. Control of CABP will 
be a challenging goal in the management of patients with cancers in bone.
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Highlights
• Osteoclasts secrete protons via membrane a3 V-H+-ATPase.
• Cancer releases proton/lactate via proton pumps and transporters.
• Extracellular environment of cancer-colonized bone is acidic.
• Sensory neurons expressing acid-sensing nociceptors innervate bone.
• Acidic environment evokes CABP by activating the nociceptors TRPV1 and 
ASIC3.
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Figure 1. Proton secretion by bone-resorbing osteoclasts
To dissolve bone minerals, mature osteoclasts release protons (H+) and chloride ions (Cl−) 
into the resorption lacunae via the plasma membrane (a3 isoform) vacuolar H+-ATPase 
proton pump [23] and chloride ion-proton anti-porter ClC-7 [24], acidifying the resorption 
lacunae to a pH of 4.5 [7]. Concomitantly, the lysosomal cysteine peptidase cathepsin K [25] 
degrades bone matrix including type I collagen.
RANKL stimulates osteoclastogenesis and bone resorption and prolongs survival by 
inhibiting apoptosis. CAII: Carbonic anhydrase II, ClC7: Plasma membrane chloride ion-
proton anti-porter, RANK: receptor activation of NF-κB, RANKL: receptor activation of 
NF-κB ligand, V-H+-ATPase: Plasma membrane (a3 isoform) vacuolar H+-ATPase proton 
pump,
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Figure 2. Vicious cycle between osteoclasts and cancer cells in bone
Bone-derived growth factors (GFs) such as insulin-like growth factors (IGF) and 
transforming growth factor-β (TGF-β), promote proliferation and inhibit apoptosis and 
stimulate epithelial-mesenchymal transition (EMT) and production of bone-modifying 
cytokines such as parathyroid hormone-related protein (PTH-rP), prostaglandin E2 (PGE2) 
and interleukin-11 (IL-11) in bone-colonizing cancer cells, representing the concept of 
“Seed and Soil” theory proposed by Paget [81]. These bone-modifying factors further 
stimulate osteoclastic bone resorption via activation of receptor activator of nuclear factor-
κB (RANKL)/RANK pathway in osteoblasts and osteoclasts, thereby further increasing 
release of bone-stored growth factors, thus establishing “vicious cycle” between bone-
resorbing osteoclasts and bone-colonizing cancer cells [1, 17, 18]. Bone-colonizing cancer 
cells reside in stromal cell niche via cell-cell contact that is mediated by cell adhesion 
molecules (CAMs) and stay dormant or undergo EMT and acquire further aggressiveness. 
Role of osteocytes in bone metastasis and CABP needs to be elucidated. CAM: cell adhesion 
molecule, EMT: Epithelial-mesenchymal transition, RANK: receptor activation of NF-κB, 
RANKL: receptor activation of NF-κB ligand,
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Figure 3. Acid-evoked cancer-associated bone pain (CABP)
Bone-resorbing osteoclasts secrete protons via plasma membrane a3 V-H+-ATPase to 
degrade bone minerals. Bone-colonizing cancer cells also release protons/lactate via MCT, 
a3 V-H+-ATPase and other proton pumps including Na+/H+ exchangers, anion exchangers, 
carbonic anhydrases, Na+/HCO3- co-transporters and HCO3-transporter to avoid 
intracellular acidification due to Warburg effect. The pH of the acidic environment created 
by cancer cells and bone-resorbing osteoclasts is assumed to be 6.5–7.0 [31] and 4.0–4.5 
[23], respectively. The acidic microenvironment directly excites and sensitizes sensory 
neurons innervating bone via activation of the acid-sensing nociceptors, TRPV1 and ASIC3, 
transducing noxious signals to via DRG (primary afferent neuron) and spinal cord 
(secondary afferent neuron) and evoke bone pain in brain.
TRPV1 activation promotes eCa2+ influx into cytoplasm and induces propagation of 
intracellular signaling molecules including calmodulin kinase II (CaMKII) and the 
transcription factor cAMP responsive element-binding protein (CREB), leading to 
transcriptional activation of target molecules [52]. TRPV1 activation also propagates Erk 
and Akt presumably to prevent apoptosis of neuron cells. Blockade of TRPV1 activation 
under the acidic cancer environments may be a promising therapeutic approach to alleviate 
CABP.
ASIC3: Acid-sensing ion channel 3, CAMKII: Calmodulin kinase II, CGRP: calcitonin 
gene-related peptide, CREB: cAMP responsive element-binding protein, DRG: Dorsal root 
ganglion, MCT: Monocarboxylate transporter, TRPV1: Transient receptor potential channel-
vanilloid subfamily member 1
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